Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Viravan Rx-to-OTC switch?

This article was originally published in The Tan Sheet

Executive Summary

PediaMed Pharmaceuticals is assessing OTC potential of its "switchable" products including its Viravan pediatric antihistamine/decongestant line, according to incoming President Cameron Durrant, MD. Durrant, whose appointment was announced Aug. 7, was VP-global business planning at Pharmacia and previously held senior positions in sales and marketing with GlaxoWellcome and Merck in the U.K. PediaMed grew from nine employees and revenue under $1 mil. in 2001 to around 75 employees and revenue in the "tens of millions" in FY 2003, according to Durrant. The new president says the firm's strengths lie in its healthy pipeline and drug delivery technology. Pediamed's only current OTC offering is Klout lice removal treatment...

You may also be interested in...

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program

In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.

Device Week, 18 September 2020 – Keeping The ‘Human’ In Human Factors Amidst COVID-19

In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts